Arcus Biosciences, Inc. (RCUS) Financial Statements
Industry: Pharmaceutical Preparations
In fiscal 2025, Arcus Biosciences reported revenue of $247.0M, down 4.3% from $258.0M the year before. Net income was -$353.0M (a -142.9% net margin), or -$3.29 per diluted share. Operating margin was -156.3%. Operating activities generated -$482.0M of cash, leaving -$484.0M of free cash flow. At fiscal year end, Arcus Biosciences held $1.14B in total assets against $508.0M in total liabilities, including $222.0M of cash and equivalents.
Open the full interactive Arcus Biosciences financials → Quarterly statements, key ratios, valuation history and price charts.
Arcus Biosciences Key Stats
| Share Price | $22.51 |
|---|---|
| Market Cap | $2.84B |
| Revenue YoY Growth | -4.3% |
| 52-Week Range | $15.62 – $31.57 |
| Shares Outstanding | 126.1 million (basic, 2026 Q2) |
Arcus Biosciences Income Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $77.5M | $382.9M | $112.0M | $117.0M | $258.0M | $247.0M |
| Operating Income | -$124.2M | $54.2M | -$280.0M | -$340.0M | -$330.0M | -$386.0M |
| Pre-Tax Income | -$122.9M | $54.6M | -$266.0M | -$301.0M | -$282.0M | -$353.0M |
| Income Tax | — | $1.8M | $1.0M | $6.0M | $1.0M | $0 |
| Net Income | -$122.9M | $52.8M | -$267.0M | -$307.0M | -$283.0M | -$353.0M |
| Diluted EPS | -$2.24 | $0.71 | -$3.71 | -$4.15 | -$3.14 | -$3.29 |
Arcus Biosciences Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $26.0M | $33.0M | $17.0M | $41.0M |
| Net Income | -$135.0M | -$106.0M | -$128.0M | -$91.0M |
| Diluted EPS | -$1.27 | -$0.99 | -$1.02 | -$0.72 |
Arcus Biosciences Balance Sheet
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $173.4M | $147.9M | $206.0M | $127.0M | $150.0M | $222.0M |
| Current Assets | $735.8M | $1.26B | $1.07B | $831.0M | $1.02B | $1.01B |
| Total Assets | $772.3M | $1.59B | $1.34B | $1.09B | $1.15B | $1.14B |
| Current Liabilities | $121.7M | $166.1M | $193.0M | $184.0M | $226.0M | $231.0M |
| Total Long-Term Debt | — | — | — | — | $48.0M | $99.0M |
| Total Liabilities | $270.0M | $750.4M | $688.0M | $633.0M | $665.0M | $508.0M |
| Shareholders' Equity | $502.3M | $841.5M | $657.0M | $462.0M | $485.0M | $631.0M |
Arcus Biosciences Cash Flow Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash From Operations | $111.2M | -$256.2M | $438.0M | -$306.0M | -$170.0M | -$482.0M |
| Cash From Investing | -$434.4M | -$3.9M | -$413.0M | $194.0M | -$84.0M | $66.0M |
| Cash From Financing | $438.7M | $237.3M | $33.0M | $33.0M | $277.0M | $488.0M |
| Free Cash Flow | $108.1M | -$282.2M | $432.0M | -$330.0M | -$176.0M | -$484.0M |
Figures from Arcus Biosciences' 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full Arcus Biosciences financials page for every line item.
Arcus Biosciences Company Profile
| Ticker | RCUS |
|---|---|
| Exchange | NYSE |
| Industry | Pharmaceutical Preparations |
| Headquarters | Hayward, California |
| Incorporated in | Delaware |
| Fiscal Year End | December 31 |
| SEC Filer Category | Large accelerated filer |
| SEC CIK | 0001724521 |
Frequently Asked Questions
What was Arcus Biosciences' revenue in fiscal 2025?
Arcus Biosciences (RCUS) reported revenue of $247.0M for fiscal 2025.
What is Arcus Biosciences' annual revenue history?
Arcus Biosciences' annual revenue by fiscal year: 2020: $77.5M; 2021: $382.9M; 2022: $112.0M; 2023: $117.0M; 2024: $258.0M; 2025: $247.0M.
What was Arcus Biosciences' net income in fiscal 2025?
Arcus Biosciences reported net income of -$353.0M for fiscal 2025.
What was Arcus Biosciences' earnings per share (EPS) in fiscal 2025?
Arcus Biosciences' diluted EPS was -$3.29 for fiscal 2025 (adjusted for any later stock splits).
How much free cash flow did Arcus Biosciences generate in fiscal 2025?
Arcus Biosciences generated -$484.0M of free cash flow in fiscal 2025.
What was Arcus Biosciences' revenue last quarter?
In its most recent reported quarter (2026 Q2), Arcus Biosciences reported revenue of $41.0M.
How much debt does Arcus Biosciences have?
Arcus Biosciences reported $99.0M of long-term debt, including the current portion, at the end of fiscal 2025.
How many shares of Arcus Biosciences are outstanding?
Arcus Biosciences reported a weighted average of 126.1 million basic shares outstanding in 2026 Q2.
What is Arcus Biosciences' market cap?
Based on its latest closing price, Arcus Biosciences (RCUS) has a market capitalization of about $2.84B.
When does Arcus Biosciences' fiscal year end?
Arcus Biosciences' fiscal year end, as registered with the SEC, is December 31.
Where is Arcus Biosciences headquartered?
Arcus Biosciences lists its business address in Hayward, California in its SEC filings.